HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 negative + PD-L1 expression	Gastric Cancer	HER-2 negative + PD-L1 expression	Gastric Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
HER-2 negative + PD-L1 expression	Gastric Cancer	HER-2 negative + PD-L1 expression	Gastric Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 negative + PD-L1 expression	Biliary Tract Cancer	HER-2 negative + PD-L1 expression	Biliary Tract Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
HER-2 negative + PD-L1 expression	Esophageal Cancer	HER-2 negative + PD-L1 expression	Esophageal Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
HER-2 negative + PD-L1 expression	Gastric Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastric Adenocarcinoma	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 negative + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	bevacizumab + SHR-1701 Sensitive: C3 – Early Trials bevacizumab + SHR-1701 Sensitive : C3	bevacizumab + SHR-1701 Sensitive: C3 – Early Trials bevacizumab + SHR-1701 Sensitive : C3
HER-2 negative + PD-L1 expression	Gastric Cancer	HER-2 negative + PD-L1 expression	Gastric Cancer	bevacizumab + SHR-1701 Sensitive: C3 – Early Trials bevacizumab + SHR-1701 Sensitive : C3	bevacizumab + SHR-1701 Sensitive: C3 – Early Trials bevacizumab + SHR-1701 Sensitive : C3
HER-2 negative + PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	HER-2 negative + PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + SHR-1701 Sensitive: C3 – Early Trials bevacizumab + SHR-1701 Sensitive : C3	bevacizumab + SHR-1701 Sensitive: C3 – Early Trials bevacizumab + SHR-1701 Sensitive : C3

HER-2 negative + PD-L1 expression

Associations